Phaseline

Companies › Cybin IRL

Cybin IRL: clinical trials, targets and expected readouts

1 active drug program in 3 registered trials: 2 Phase 3, 1 Phase 2; Psychiatry; next expected readout Jun 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
CYB003
Deuterated psilocin analog
HTR2APhase 3Major Depressive Disorder; Major Depressive Disorder (MDD); DepressionJun 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06564818CYB003Phase 3Major Depressive DisorderPsychiatrySep 2026
NCT06793397CYB003Phase 3Major Depressive Disorder (MDD)PsychiatryJun 2027
NCT06820723CYB003Phase 2DepressionPsychiatryNov 2028

Targets

HTR2A (1)

Companies with the same targets

COMPASS Pathways ACADIA Pharmaceuticals Vanda Pharmaceuticals Intra-Cellular Therapies Definium Therapeutics US Sichuan Kelun Pharmaceutical Boryung Pharmaceutical Otsuka NeuroRx Tonix Pharmaceuticals

Companies built like this

NeuroRx Intra-Cellular Therapies COMPASS Pathways Gedeon Richter Beijing Union Pharmaceutical Factory

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.